Pathophysiological impairment of the neurovascular unit, including the integrity and dynamics of the blood-brain barrier (BBB), has been denoted both a cause and consequence of neurodegenerative diseases. Pathological impact on BBB drug delivery has also been debated. The aim of the present study was to investigate BBB drug transport, by determining the unbound brain-to-plasma concentration ratio (K p,uu,brain ), in aged AbPP-transgenic mice, a-synuclein transgenic mice, and wild type mice.
Introduction
Since the early 1900's it has become increasingly recognized that a physical and highly dynamic barrier hinders the passage of constituents from the circulation into the brain (Saunders et al., 2014) . Today this barrier is well known as the blood-brain barrier (BBB), consisting of the thin but tightly joined layer of endothelial cells, constituting the capillary walls of the brain. Together with other brain parenchymal cells and structures, the endothelial cells form the neurovascular unit (NVU) (Neuwelt et al., 2011) . The NVU plays an important role in maintaining the minute microenvironment required within the brain for normal neuronal functioning. Active and passive transport mechanisms at the BBB aid in the uptake of essential molecules from the blood to the brain. However, much of the activity at the BBB is dominated by efficient efflux transport, acting in parallel with tight and adherens junctions, metabolism, low pinocytotic activity, bulk flow and the charge of the glycocalyx to restrict exogenous and endogenous molecules from entering the brain.
Pathophysiological impairment of the BBB and the NVU has been suggested in neurodegenerative diseases (Zhao et al., 2015) . Terms like "BBB breakdown" and "a leaking barrier" are also becoming increasingly acknowledged. Accordingly, NVU dysfunction, reduction of tight junctions, and impaired efflux transport in both in vitro and in vivo studies, speaks in favor of an affected BBB permeability in disorders like Alzheimer's disease and Parkinson's disease (Farkas et al., 2000; Kortekaas et al., 2005; Bartels et al., 2008b; Mehta et al., 2015; van de Haar et al., 2016) . Consequently, an altered drug transport across the BBB under such disease conditions has been postulated, with enhanced or reduced effect or side effects as potential outcomes. However, conflicting evidence question how and to what extent the NVU is compromised and how this might affect drug delivery to the brain and ultimately the treatment of patients (Bourasset et al., 2009; Cheng et al., 2010; Mehta et al., 2013a; Bien-Ly et al., 2015) .
Brain drug delivery can be investigated by the means of rate or extent of drug transport across the BBB . While the rate could be important for a fast onset of effect, most dose regimens are aimed for continuous and daily treatment where the extent of drug transport into the brain might be of higher significance . For valid measurements of drug BBB transport it is of uttermost importance to investigate the unbound concentrations of drug that are present within brain and plasma, as it is only the unbound drug that can cross the barrier and later also drive the therapeutic effect (Gupta et al., 2006; Summerfield et al., 2006; Kalvass et al., 2007a Kalvass et al., , 2007b Liu et al., 2009) .
While BBB transport of drug molecules is difficult to study in humans, animal models are used in basic research and drug development to elucidate the pharmacokinetic properties of compounds under different disease conditions. One such disease model is the transgenic mouse tg-APP ArcSwe , carrying both the Swedish (p. KM670/671NL) and the Arctic (p. E693G) mutations of the amyloidb precursor protein (AbPP) observed in familial forms of Alzheimer's disease (Lord et al., 2006) . The tg-APP ArcSwe mice express high brain levels of amyloid beta (Ab) and the proposed neurotoxic and soluble Ab oligomers and protofibrils (Nilsberth et al., 2001; Lord et al., 2006 ). An advantage compared to many other models of Ab pathology, is that the plaques, that start to develop in the tg-APP ArcSwe brain at an age of 6e7 months, are dense core plaques, resembling those observed in most forms of human Alzheimer's disease. In addition, the model also displays cerebral amyloid angiopathy (Philipson et al., 2009 ). Another disease model, tgaSYN A30P , used for the investigation of a-synuclein related disorders, express a-synuclein with the missense mutation Ala30Pro that is found in one family with dominantly inherited Parkinson's disease (Kahle et al., 2001 ). This transgene exhibits overexpression of human a-synuclein, with the further formation of potentially toxic soluble a-synuclein aggregates, such as oligomers and protofibrils (Kahle et al., 2000; Neumann et al., 2002; Fagerqvist et al., 2013) . Aggregated a-synuclein is found in the tg-aSYN A30P brain from the age of 12 months.
By investigating the plasma and brain pharmacokinetic properties of a cassette of compounds in these animal models, the current study aimed to elucidate how pathological hallmarks of neurodegenerative diseases might influence the extent of transport of small molecular drugs across the BBB. The compounds investigated in the current study were chosen with regard to their net transport across the BBB, as indicated by their K p,uu,brain values. In order to detect any change in passive permeability at the BBB, diazepam was chosen as a model compound, with a K p,uu,brain close to unity (Friden et al., 2009 ). Owing to extensive findings of altered expression and functional changes of efflux transporters during CNS disorders, levofloxacin, paliperidone and digoxin were examined as they all show a net active efflux at the BBB, where the two latter are confirmed substrates of P-glycoprotein (P-gp) (Schinkel et al., 1995; Wang et al., 2004; Friden et al., 2009) . As little is known about the active uptake of small molecular drugs during disease, oxycodone was chosen as a marker of net active influx at the BBB (Bostrom et al., 2006) .
Materials and methods

Chemicals
Oxycodone hydrochloride and diazepam were obtained from APL (Stockholm, Sweden). Digoxin was obtained from Apoteket AB (Solna, Sweden). Levofloxacin and paliperidone, both of analytical grade, were purchased from Sigma Aldrich (St. Louis, MO, USA). The internal standards diazepam-D5 and oxycodone-D6, used in the sample analysis, were purchased from Cerilliant Corporation (Round Rock, Texas, USA). Phosphate buffered saline (PBS) tablets of 0.01 M, pH 7.4, were used for perfusions and purchased from Medicago (Uppsala, Sweden). Acetonitrile (ACN) (Merck, Darmstadt, Germany) was of gradient grade and all other chemicals were of analytical grade. The water used was deionized in house and further purified with a Milli-Q Academic system (Millipore, Bedford, MA, USA).
Animals
In the current study, male and female (11:10) homozygous (Thy-1)-h[A30P] a-SYN transgenic mice (tg-aSYN A30P ) (Kahle et al., 2000 (Kahle et al., , 2001 , overexpressing A30P mutated human a-synuclein, were used, as well as heterozygous male and female (8:9) (Thy-1)-h [E693G; KM670/671NL] AbPP transgenic mice (tg-APP ArcSwe ) (Lord et al., 2006) , expressing AbPP with the human Arctic (E693G) (Nilsberth et al., 2001) and Swedish (KM670/671NL) (Mullan et al., 1992) mutations. Non-transgenic male and female (51:46), C57BL/ 6J wild type (WT) mice were used for validation and as controls. All animals were on a C57BL/6J background and all animals were bred in house. The animals were housed in a humidity and temperature controlled environment on a 12 h light/dark cycle 
Experimental set up for cassette validation
Levofloxacin, paliperidone, digoxin, diazepam and oxycodone were chosen as model compounds in the present study. Before used in disease models, the total brain-to-plasma concentration ratio (K p,brain ) was determined for all compounds after discrete or cassette dosing in order to validate the pharmacokinetic properties of the drugs when given alone or in combination with other drugs. The five model compounds were dissolved in 2.5% ethanol, 0.21% acetic acid and 97% PBS, both when prepared as a cassette and when compounds were prepared for discrete dosing. For the cassette validation, 2e5 months old WT mice were administered a subcutaneous dose of the compounds as discrete doses or as a cassette at a dose of 0.25 mg/kg for oxycodone and diazepam, and 1 mg/kg for digoxin and levofloxacin. Paliperidone was administered at a dose of 1 mg/kg in the discrete dosing experiment but the dose was lowered to 0.25 mg/kg when included in the cassette in order to minimize CNS effects when three CNS active compounds were administered simultaneously. The volume of dose solution administered to all animals was 8 mL/g body weight. The animals were euthanized at 0.5 h, 1 h, and 3 h after dose (n ¼ 3e4 per time point). Blood was collected through cardiocentesis and brains were extracted following transcardial 0.01 M PBS perfusion. Blood samples were centrifuged at 7200 g for 5 min. Plasma was collected and directly frozen on dry ice. The brains were further dissected on ice. The dissection was performed in order to extract areas of the brain with pathological relevance for the animal models later used in other experiments. Briefly, the left and right hemispheres were separated and cerebellum and the olfactory bulb of the right hemisphere were removed. The right hemisphere was further divided in two pieces that generated a caudal part involving pathologically affected brain regions such as hippocampus and thalamus for the tg-APP ArcSwe mice, and the midbrain and brainstem found to be affected in the tg-aSYN A30P mice (Freichel et al., 2007; Lillehaug et al., 2014) . The samples were frozen on dry ice and all samples were stored at À80 C until analysis.
Experimental setup for estimation of K p,brain in transgenes and WT animals
The K p,brain was determined by terminal brain and plasma sampling in tg-aSYN A30P mice at an age of 16e19 months, as well as in 16 months old tg-APP ArcSwe and WT mice. The animals were administered a subcutaneous dose of the cassette compounds at doses of 0.25 mg/kg for oxycodone, diazepam and paliperidone, and 1 mg/kg for digoxin and levofloxacin. The animals were euthanized at 0.5 h (n tg-APP ArcSwe ¼ 3, tg-aSYN A30P ¼ 5, and WT ¼ 3), 1 h (tg-APP ArcSwe ¼ 5, tg-aSYN A30P ¼ 5, and WT ¼ 5), and 3 h (tg-APP ArcSwe ¼ 3, tg-aSYN A30P ¼ 5, and WT ¼ 3) after dose. Blood and brain were collected and processed as described in section 2.3.
Brain and plasma sample preparation
Sample preparation was carried out just before analysis. Plasma samples were thawed in room temperature, vortexed and centrifuged for 1 min at 10 000 g. Brain samples were homogenized by diluting the tissue 5-fold in buffer (180 mM phosphate buffer, pH 7.4) and by the use of a high intensity ultrasonic processor (VibraCell, Sonics & Materials Inc., Newtown, CT, USA). The brain homogenate was then briefly vortexed. Fifty mL of sample was precipitated with 150 mL of ACN, containing 0.2% formic acid and the internal standards diazepam-D5 and oxycodone-D6 at concentrations of 20 ng/mL. The samples were mixed and centrifuged for 3 min at 10 000 g. One hundred fifty mL of supernatant was transferred to a new tube and evaporated under a stream of nitrogen at 40 C. For the plasma samples, the residual was dissolved in 30 mL of ACN and 300 mL of 5 mM ammonium formate buffer, pH 3.4. The residual of the brain homogenate samples were dissolved in 20 mL of ACN and 200 mL of 5 mM ammonium formate buffer. All samples were mixed and centrifuged at 10 000 g for 1 min and transferred into autosampler vials. For the analysis of levofloxacin and paliperidone in plasma, 15 mL were injected on to a column, while 40 mL was injected for the analysis of diazepam and diazepam-D5. For the analysis of digoxin, oxycodone, and oxycodone-D6 in plasma, 20 mL and 40 mL were injected onto the column, respectively. For concentration measurements in brain, 75 mL was injected for the analysis of levofloxacin, paliperidone, diazepam, diazepam-D5, and digoxin. For the analysis of oxycodone and oxycodone-D6 in brain, 40 mL was injected onto the column.
Brain tissue and plasma protein binding
The fraction of unbound drug was determined in plasma and in brain tissue from the caudal right hemisphere of 16e19 months old tg-aSYN A30P , and of 16 months old tg-APP ArcSwe and WT mice, and in the rostral right hemisphere of the same tg-APP ArcSwe and WT mice (number of animals for plasma ¼ 6e8, and brain ¼ 6 per group). Dialysis membrane strips with a molecular weight cut off of 12e14 kDa (HTDialysis LLC, Gales Ferry, CT, USA) were conditioned in 180 mM phosphate buffer, pH 7.4, overnight and rinsed again with fresh phosphate buffer before use. Brain tissue homogenate was prepared from the rostral and caudal part of the right hemisphere by diluting the tissue samples 5-fold with buffer (180 mM phosphate buffer, pH 7.4). The tissue samples were homogenized using a high intensity ultrasonic processor (Vibra-Cell, Sonics & Materials Inc., Newtown, CT, USA). Due to the limited amount of tissue and plasma from each animal, samples were pooled within each group, in order to avoid extensive dilution of the samples and to retrieve sufficient technical replicates. The plasma was adjusted to 37 C in a water bath and the pH was adjusted to 7.2 by the use of 1 M phosphoric acid. After handling of the samples and hence after exposure to air, the pH reached 7.4. The brain homogenate and plasma from all groups were spiked with the five cassette compounds to a final concentration of 1 mM, and 125 mL aliquots were loaded in five replicates into a 96-well equilibrium dialysis apparatus (HTDialysis LLC, Gales Ferry, CT, USA). Dialysis against the same volume of 180 mM phosphate buffer, pH 7.4 was carried out for 6 h at 37 C, at 200 rpm in a MaxQ 4450 benchtop shaker (Thermo Scientific, Waltham, MA, USA). Adhesive sealing film (HTDialysis LLC, Gales Ferry, CT, USA) was used to cover the samples to prevent evaporation, pH changes, and contamination during dialysis. At the end of the incubation period, samples were collected from all chambers and the matrix in brain homogenate, plasma or buffer was balanced with the corresponding opposite fluid before stored at À20 C until analysis.
Equilibrium dialysis sample preparation
Sample preparation was carried out just before analysis. Plasma samples were vortexed and centrifuged for 1 min at 10 000 g.
Homogenate samples were vortexed only. Fifty mL of sample was precipitated with 150 mL of ACN, containing 0.2% formic acid, and the internal standards diazepam-D5 and oxycodone-D6 at concentrations of 20 ng/mL. The samples were mixed and centrifuged for 3 min at 10 000 g. One hundred mL of supernatant was mixed with 600 mL 5 mM ammonium formate buffer, pH 3.4. For the later analysis of compounds, 40 mL was injected onto the column.
Liquid chromatography-tandem mass spectrometry analysis
The quantitative analysis was carried out on a liquid chromatography-tandem mass spectrometry (LC-MS/MS) system. The analytical methods were developed by optimizing the parameters to obtain a high resolution in a reasonable analysis time. The LC system included a SIL-HTc autosampler (Schimadzu, Kyoto, Japan) and one or two LC-10ADvp pumps connected to the column. A Zorbax Eclipse XDB-CN column (4.6 Â 150 mm; Agilent Technologies, Santa Clara, CA, USA), maintained at 50 C, was used when analyzing oxycodone and oxycodone-D6. The mobile phase consisted of 45% ACN in 5 mM ammonium acetate and a constant flow rate of 1.0 mL/min was used. The flow was split, allowing 0.2 mL/ min to enter the detector. The detector was a Quattro Ultima Pt Triple Quadrupole Mass Spectrometer (Waters, Milford, MA, USA). When analyzing levofloxacin, paliperidone, diazepam, diazepam-D5, and digoxin a HyPURITY C18 column (50 Â 4.6 mm; Thermo Hypersil-Keystone, Bellefonte, PA, USA) was used with a guard column in the same material placed before the analytical column. A gradient run was applied when analyzing levofloxacin, paliperidone, diazepam and diazepam-D5. Mobile phases A (MPA) consisted of 5 mM ammonium formate buffer, pH 3.4, and mobile phase B (MPB) consisted of ACN:5 mM ammonium formate buffer (90:10). The gradient started with 90% MPA and 10% MPB, switching to 80% MPA and 20% MPB, and to 10% MPA and 90% MPB after 1 min and 4 min, respectively, returning back to 90% MPA and 10% MPB at 4.5 min. Digoxin was analyzed under isocratic conditions using the same two aforementioned mobile phases, MPA and MPB (66:34). The flow rate was set to 0.8 mL/min and split to 0.3 mL/min before entering the mass spectrometer. The analysis was carried out in a positive ionization mode using multiple reaction monitoring for all of the compounds. The transition modes for oxycodone and oxycodone-D6 were set to m/z 316.0 to m/z 297.9 and 322.1 to m/z 303.9, respectively. The transition modes for diazepam and diazepam-D5 were set to m/z 284.9 to m/z 154 and 290 to m/z 154, respectively. The transition modes for levofloxacin, paliperidone and digoxin were set to m/z 362.05 to m/z 318.05, m/z 427 to m/z 207, and m/z 798.2 to m/z 651.3, respectively. Mass spectrometry control and spectral processing for determination of compound concentrations were carried out using MassLynx software version 4.1 in combination with the Application Manager QuanLynx (Waters Corporation, Milford, MA, USA). The standard curves for all compounds showed good linearity (coefficient of determination > 0.990) and all samples were within the linear range.
2.9. Ab and a-synuclein ELISA Brain concentrations of total Ab were measured in the tg-APP ArcSwe and the WT animals, and total a-synuclein was measured in the tg-aSYN A30P and WT animals as described previously, with modifications (Fagerqvist et al., 2013; Sehlin et al., 2016) . Briefly, for ELISA measurement of Ab1-40 and Ab1-42, 96-well plates were coated with 100 ng per well of polyclonal rabbit anti-Ab40 or antiAb42 (Agrisera, Umeå, Sweden). For ELISA measurement of a-synuclein, 96-well plates were coated with 50 ng per well of Syn-1 (BD Biosciences, Franklin lake, NJ, USA). All plates were coated overnight at 4 C. Unspecific binding was blocked with 1% BSA the next day. The left hemisphere of each animal involved in the study was homogenized at a 1:5 weight:volume ratio in TBS with complete protease inhibitors (Roche, Basel, Switzerland). The tissues were homogenized in 2 mL homogenization tubes containing 1.4 mm ceramic beads using a Precellys Evolution homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). 62 mL of the TBS extract was mixed with 167 mL of concentrated formic acid, to a final formic acid concentration of 70%, followed by vortexing and centrifugation for 1 h at 16 000 g, at 4 C. Formic acid extracts were neutralized with 2 M Tris and diluted 2000 or 20 000 times, for Ab1-42 and Ab1-40, respectively, and 5000 times for a-synuclein.
Samples were loaded on the plates and incubated overnight at 4 C, followed by detection with biotinylated 82E1, (0.25 mg/mL; IBL International/Tecan Trading AG, Switzerland) and streptavidin-HRP (1:5000; Mabtech AB, Nacka Strand, Sweden) for Ab1-42 and Ab1-40. For the detection of a-synuclein a rabbit IgG anti-a-synuclein polyclonal antibody, FL140 (1: 1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a polyclonal HRP-coupled goatanti-rabbit IgG antibody (1: 1000; Pierce, Rockford, IL, USA) were used. Signals were developed with K blue aqueous TMB substrate (Neogen Corp., Lexington, KY, USA), the reaction was stopped using 1 M H 2 SO 4 , and the signal was read with a spectrophotometer at 450 nm. All samples and secondary antibodies were diluted in ELISA incubation buffer (PBS with 0.1% BSA, 0.05% Tween and 0.15% proclin). The wells were washed three times between each step with ELISA washing buffer (phosphate-buffered NaCl with 0.1% Tween 20 and 0.15% proclin).
Data analysis
The total brain-to-plasma concentration ratio, K p,brain , was calculated (Eq. (1)) based on the area under the concentration-time curves (AUC) from 0 to 3 h of the brain and plasma profiles, estimated by the linear-trapezoidal method. As the AUC estimates are based on mean concentrations of terminal brain and plasma samples at each time point, the K p,brain is presented as a single value without standard deviation (SD). However, the coefficient of variation (CV) in the brain-to-plasma concentration ratio at each time point was approximately 20% (Supplementary Table 1 ).
The fraction of unbound drug in plasma, f u,plasma , was calculated, from the equilibrium dialysis experiments, as the buffer-to-plasma concentration ratio (Eq. (2)).
The fraction of unbound drug in diluted brain homogenate, f u,hD , was calculated as the buffer-to-homogenate concentration ratio (Eq. (3)). f u,hD was further used to calculate the fraction of unbound drug in brain, f u,brain (Eq. (4)), while also accounting for the dilution factor, D, of the brain homogenate.
The unbound brain-to-plasma concentration ratio, K p,uu,brain , used to estimate net BBB transport, was calculated by combining the K p,brain estimates with the fractions of unbound drug in brain and plasma as given by Equation (5).
3. Results
Cassette validation
The five drugs, levofloxacin, paliperidone, digoxin, diazepam, and oxycodone were investigated in WT animals, at an age of 2e5 months, for the presence or absence of drug-drug interactions, as they were to be administered as a cassette to reduce the number of animals required in the following experiments. The K p,brain values, representing total brain-to-plasma concentration ratios, estimated from the cassette dosing, were within 2-fold of the values of the discrete dosing for all of the five compounds investigated. Concluding that the compounds could be administered as a cassette (Fig. 1). Fig. 2 ). Digoxin and paliperidone are targets of P-gp and together with levofloxacin showed a net efflux at the BBB, indicated by K p,uu,brain values below unity, as expected. No difference in the BBB transport was observed for these three compounds when comparing tg-APP ArcSwe mice and tg-aSYN A30P mice with age matched controls. Statistical comparison of the values was not applicable due to terminal sampling and pooling of data at each time point for the estimation of brain and plasma AUC, used for the K p,brain calculations. However, the differences in K p,uu,brain values between the groups were so small that the likeliness of an affected efflux transport for these compounds can be regarded as insignificant. The plasma concentration-time profiles did not differ between healthy animals and transgenes for any of the compounds.
BBB transport in tg-
Diazepam is a lipophilic drug with an estimated K p,uu,brain value close to unity in the current study, supporting passive diffusion as the dominating transport of diazepam. The extent of transport of diazepam across the BBB did not differ for any of the two transgenes compared to WT animals (Table 1, Fig. 2 ) and there were no pronounced differences in the plasma concentration profiles when comparing WT animals to transgenes.
Oxycodone, displaying net active uptake, showed K p,uu,brain values around 2 for all groups (Table 1, Fig. 2) , with no differences in the plasma concentration-time profiles. Hence, independent of transgene no differences in BBB transport was observed, indicating a preserved active uptake transport of oxycodone at the BBB.
Brain tissue binding in rostral and caudal brain regions
In order to investigate any differences in drug binding properties due to the brain distribution of Ab pathology or due to heterogeneity in regional brain composition, drug tissue binding was investigated in rostral and caudal brain areas from 16 months old tg-APP ArcSwe and WT mice (Fig. 3) . There was no difference in the tissue binding when comparing rostral and caudal brain for paliperidone, digoxin, diazepam and oxycodone in neither WT nor transgenic animals. Nor was there any difference in tissue binding when comparing WT with transgenes. Levofloxacin was excluded in this part of the study due to technical difficulties caused by very low binding.
Ab and a-synuclein pathology in transgenic mice
The presence of pathology was confirmed in the tg-APP ArcSwe mice with total Ab40 and Ab42 levels of 285 ± 85 and 8.9 ± 2.7 ng/ mg brain (mean ± SD), respectively (Fig. 4a) , and with undetectable amounts in WT animals. a-synuclein pathology was also confirmed with total a-synuclein levels of 1656 ± 591 ng/mg brain in the tgaSYN A30P mice and 129 ± 21 in WT mice (Fig. 4b) . The a-synuclein detected in WT mice is most probably endogenous mouse a-synuclein detected by the ELISA.
Discussion
Accumulating evidence suggests an impairment of the NVU, and in particular the BBB, during CNS related disorders (Daneman, 2012; Zhao et al., 2015) , which would indicate an altered drug transport at the BBB. By investigating drugs with different routes of BBB transport in animal models expressing Ab or a-synuclein pathology, our current study shows that the extent of BBB transport of small molecular drugs was unaffected in disease compared to healthy conditions. Hence, the present study suggests that the concept of a leaking barrier should be considered with caution for small molecular drugs under neurodegenerative conditions. It also indicates that the capacity of the highly dynamic BBB is sufficient for normal regulation of drug transport despite pathological influence.
In order to reduce the number of animals used in this study, the compounds were administered as a cassette. Cassette dosing also adds to the advantage of investigating all BBB transport mechanisms in the same animals, thereby minimizing group-related differences. The drugs in the cassette can also act as internal controls in the analysis. While some of the drugs constitute targets of the same transporter at the BBB, simultaneous administration of the drugs did not indicate any interactions affecting the neuropharmacokinetic properties of the compounds compared to discrete dosing. Furthermore, terminal blood and brain sampling was used in the current study, resulting in pooling of data where the inter-individual variability is lost when using noncompartmental analysis. However, despite the lack of interindividual variation, we believe that any profound difference in drug neuropharmacokinetic properties in transgenes compared to WT would be noted under the current experimental conditions, given the similarity in pharmacokinetic profiles and the high expression of toxic Ab or a-synuclein species.
Pathological impact on efflux transport was investigated by the Fig. 1 . Relationship between the total brain-to-plasma concentration ratio, K p,brain , determined from discrete and cassette dosing of the five model compounds in WT animals, 2e5 months old. The solid line represents the line of identity. The dashed lines represent a 2-fold deviation from unity. Dig, digoxin; Lev, levofloxacin; Pal, paliperidone; Diaz, diazepam; Oxy, oxycodone.
use of digoxin, paliperidone, and levofloxacin, which all display a net active efflux at the BBB and where the two former constitutes substrates of P-gp. Despite the confirmed presence of toxic Ab species and plaques in the brain of the tg-APP ArcSwe mice, no difference was observed in the extent of transport of these compounds across the BBB compared to healthy, age matched controls. Numerous studies report Ab influence on BBB integrity and P-gp expression. In vitro findings, using brain endothelial cells have shown a reduced expression of tight junction proteins and increased permeability of high molecular weight compounds upon treatment with different Ab species (Marco and Skaper, 2006; Gonzalez-Velasquez et al., 2008; Tai et al., 2010; Carrano et al., 2011 ). An altered expression of P-gp on both mRNA and protein levels in endothelial cells were also shown but seem to be dependent on Ab concentrations (Kania et al., 2011; Qosa et al., 2014) . Furthermore, in vivo studies in transgenic models of Alzheimer's disease report disruption of tight junctions and an approximately 60% reduction of P-gp expression in isolated brain microvessels of Tg2576 mice, as well as a 42% reduction of P-gp expression in the 3xTg AD mouse model (Hartz et al., 2010; Biron et al., 2011; Mehta et al., 2013a) . However, despite the reduction of P-gp expression in the 3xTg mice, there was no change in the rate of transport of digoxin across the BBB, which is in line with our current findings (Mehta et al., 2013a) . Together with our present study, the results in the 3xTg mice suggest that the remaining transporter capacity is sufficient to maintain an appropriate drug efflux at the BBB. In contrary to the aforementioned findings, Do et al. observed an age dependent upregulation of P-gp in brain capillaries of the 3xTg mice and a tendency towards reduced Oatp1a4 was also reported (Do et al., 2016) . Since the net transport of digoxin, a substrate of both transporters, was not changed in the current study, it was not possible to distinguish individual transporter impact in the present study. In line with Ab pathology, aggregated a-synuclein did not influence net transport of digoxin, levofloxacin, and paliperidone.
Hence, these results indicate that the expression of Ab or a-synuclein pathology alone do not affect the investigated efflux properties to such an extent that drug transport is altered at the BBB at in vivo relevant doses. Diazepam was used in the present study as a marker of transcellular transport by the means of passive diffusion, supported by a K p,uu,brain close to unity. No difference was observed in the transport of diazepam across the BBB in any of the transgenic models compared to controls. Hence, the present Ab or a-synuclein pathology does not have a major impact on the extent of transcellular passive drug transport across the BBB. In support of our findings, no difference was observed in passive diffusional BBB transport in a previous study using animal models exhibiting Ab plaque disposition or stimulated tau pathology (Cheng et al., 2010) . A reduction in the rate of diazepam transport across the BBB has been observed in the 3xTg mouse model of Alzheimer's disease, said to be caused by a thickening of the basement membrane (Mehta et al., 2013a) . However, in a different study, using the 3xTg model, no difference was found in diazepam transport rate compared to controls (Bourasset et al., 2009) .
To examine possible changes in net active uptake at the BBB, oxycodone was investigated in the present study. However, independent of transgene, the transport of oxycodone was the same as in WT mice. Oxycodone is transported by an energy-dependent, proton-coupled antiporter at the BBB (Bostrom et al., 2006; Okura et al., 2008) . Memantine is a drug that also shows active uptake at the BBB and is transported by the same system as oxycodone (Hesselink et al., 1999; Mehta et al., 2013b; Higuchi et al., 2015) . The rate of BBB transport of memantine has been studied and was decreased in an animal model of Alzheimer's disease, possibly due to a thickening of the basement membrane (Mehta et al., 2013c ). While we did not observe any change in oxycodone brain uptake when considering the extent of transport, this points to the importance of investigating both rate and extent of drug transport at the BBB. Hence, the uptake mechanisms appear to be intact under current disease conditions and at the administered doses.
Overall, our study shows that increased Ab or a-synuclein expression alone does not affect the BBB to such an extent that the transport of the drugs studied is altered. This is partly in line with recent findings in humans with cognitive impairment, which indicate that amyloid pathology alone is not sufficient for BBB permeability changes (Janelidze et al., 2016) . In further support of our data, studies show no difference in the distribution of large molecules to the brain in a variety of Alzheimer's disease mouse models compared to controls (St-Amour et al., 2013; Alata et al., 2015; Bien-Ly et al., 2015) . Still, it is important to stress that the animal models used in the current study, display only parts of the respective diseases. It cannot be fully ruled out that changes in brain drug delivery of compounds are altered in patients with Alzheimer's disease, where tau pathology is also extensive and where the disease is dependent on a multitude of factors, or in patients with different forms of a-synucleinopathies. In a study by Janelidze et al., permeability changes during Alzheimer's disease were not shown to be associated with APOE genotype in humans (Janelidze et al., 2016) , while this has previously been suggested by Halliday et al. (2016) . However, as studies of APOE4 animal models also show cerebrovascular changes and altered NVU properties, the impact of APOE on small molecular drug transport needs further evaluation in both animals and humans (Bell et al., 2012; Alata et al., 2015) . In addition, the influence of tau pathology on BBB functioning and the extent of brain drug delivery needs further investigation as abnormalities in brain vascular volume and BBB transporter expression has been presented in the 3xTg mouse model, also exhibiting tau pathology (Do et al., 2014 (Do et al., , 2016 . Furthermore, in a study by Vogelgesang et al., an inverse correlation between cerebrovascular P-gp expression and the deposition of Ab was observed in aged human tissue (Vogelgesang et al., 2002) . In later studies, P-gp has also been suggested to be reduced in human brain tissue from Alzheimer patients (Wijesuriya et al., 2010; Chiu et al., 2015) . Clinical positron emission tomography studies further suggest a reduced P-gp function at the BBB in patients with Alzheimer's disease, and while P-gp function does not seem to be impaired in early stages of Parkinson's disease, a reduction seems to be apparent in more advanced Parkinson patients (Kortekaas et al., 2005; Bartels et al., 2008a Bartels et al., , 2008b van Assema et al., 2012; Deo et al., 2014) . A thickening of the basement membrane was also observed in patients with Alzheimer's or Parkinson's disease (Farkas et al., 2000) , which would primarily influence the rate of drug delivery to the brain as observed by Mehta and coworkers (Mehta et al., 2013c, a) . As differences in BBB transport properties on a regional level have been suggested under both healthy and disease conditions, studies relating brain regional pathology to local drug concentrations is also essential in both animals and humans (Jeynes and Provias, 2013; Loryan et al., 2016) . In the present study, areas of the brain subjected to pathological hallmarks were analyzed for differences in drug brain binding. However, no profound differences were observed for any of the compounds investigated.
In conclusion, no difference was observed in the extent of transport of small molecular drugs, transported across the BBB by several active or passive transport mechanisms, in animals displaying Ab or a-synuclein pathology compared to healthy WT animals. The present study highlights the importance of further neuropharmacokinetic assessment of drugs in patients. Hence, altered NVU function and its impact on BBB drug transport at clinically relevant drug concentrations needs to be evaluated in humans. The present study also indicates that the human BBB may be capable of balancing drug transport in spite of pathological insults. In addition, changes in pharmacodynamic properties as well as pharmacokinetics must be investigated if altered effect or side effect profiles are observed under pathological conditions.
